Neurological manifestations of COVID-19 and other coronaviruses : A systematic review
© 2020 Elsevier GmbH. All rights reserved..
OBJECTIVE: To describe the main neurological manifestations related to coronavirus infection in humans.
METHODOLOGY: A systematic review was conducted regarding clinical studies on cases that had neurological manifestations associated with COVID-19 and other coronaviruses. The search was carried out in the electronic databases PubMed, Scopus, Embase, and LILACS with the following keywords: "coronavirus" or "Sars-CoV-2" or "COVID-19" and "neurologic manifestations" or "neurological symptoms" or "meningitis" or "encephalitis" or "encephalopathy," following the Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
RESULTS: Seven studies were included. Neurological alterations after CoV infection may vary from 17.3% to 36.4% and, in the pediatric age range, encephalitis may be as frequent as respiratory disorders, affecting 11 % and 12 % of patients, respectively. The Investigation included 409 patients diagnosed with CoV infection who presented neurological symptoms, with median age range varying from 3 to 62 years. The main neurological alterations were headache (69; 16.8 %), dizziness (57, 13.9 %), altered consciousness (46; 11.2 %), vomiting (26; 6.3 %), epileptic crises (7; 1.7 %), neuralgia (5; 1.2 %), and ataxia (3; 0.7 %). The main presumed diagnoses were acute viral meningitis/encephalitis in 25 (6.1 %) patients, hypoxic encephalopathy in 23 (5.6 %) patients, acute cerebrovascular disease in 6 (1.4 %) patients, 1 (0.2 %) patient with possible acute disseminated encephalomyelitis, 1 (0.2 %) patient with acute necrotizing hemorrhagic encephalopathy, and 2 (1.4 %) patients with CoV related to Guillain-Barré syndrome.
CONCLUSION: Coronaviruses have important neurotropic potential and they cause neurological alterations that range from mild to severe. The main neurological manifestations found were headache, dizziness and altered consciousness.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Neurology, psychiatry, and brain research - 37(2020) vom: 15. Sept., Seite 27-32 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Correia, Alyne Oliveira [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 28.03.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.npbr.2020.05.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314079548 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314079548 | ||
| 003 | DE-627 | ||
| 005 | 20240328235700.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.npbr.2020.05.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM314079548 | ||
| 035 | |a (NLM)32834527 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Correia, Alyne Oliveira |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neurological manifestations of COVID-19 and other coronaviruses |b A systematic review |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2020 Elsevier GmbH. All rights reserved. | ||
| 520 | |a OBJECTIVE: To describe the main neurological manifestations related to coronavirus infection in humans | ||
| 520 | |a METHODOLOGY: A systematic review was conducted regarding clinical studies on cases that had neurological manifestations associated with COVID-19 and other coronaviruses. The search was carried out in the electronic databases PubMed, Scopus, Embase, and LILACS with the following keywords: "coronavirus" or "Sars-CoV-2" or "COVID-19" and "neurologic manifestations" or "neurological symptoms" or "meningitis" or "encephalitis" or "encephalopathy," following the Systematic Reviews and Meta-Analyses (PRISMA) guidelines | ||
| 520 | |a RESULTS: Seven studies were included. Neurological alterations after CoV infection may vary from 17.3% to 36.4% and, in the pediatric age range, encephalitis may be as frequent as respiratory disorders, affecting 11 % and 12 % of patients, respectively. The Investigation included 409 patients diagnosed with CoV infection who presented neurological symptoms, with median age range varying from 3 to 62 years. The main neurological alterations were headache (69; 16.8 %), dizziness (57, 13.9 %), altered consciousness (46; 11.2 %), vomiting (26; 6.3 %), epileptic crises (7; 1.7 %), neuralgia (5; 1.2 %), and ataxia (3; 0.7 %). The main presumed diagnoses were acute viral meningitis/encephalitis in 25 (6.1 %) patients, hypoxic encephalopathy in 23 (5.6 %) patients, acute cerebrovascular disease in 6 (1.4 %) patients, 1 (0.2 %) patient with possible acute disseminated encephalomyelitis, 1 (0.2 %) patient with acute necrotizing hemorrhagic encephalopathy, and 2 (1.4 %) patients with CoV related to Guillain-Barré syndrome | ||
| 520 | |a CONCLUSION: Coronaviruses have important neurotropic potential and they cause neurological alterations that range from mild to severe. The main neurological manifestations found were headache, dizziness and altered consciousness | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ACE2, angiotensin converting enzyme 2 | |
| 650 | 4 | |a ADEM, acute disseminated encephalomyelitis | |
| 650 | 4 | |a ANHE, acute necrotizing hemorrhagic encephalopathy | |
| 650 | 4 | |a BBE, Bickerstaff’s encephalitis | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19, coronavirus disease 2019 | |
| 650 | 4 | |a CoV, coronavirus | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a DPP4, dipeptidil peptidase 4 | |
| 650 | 4 | |a Encephalopathy | |
| 650 | 4 | |a G-CSF, granulocyte colony stimulating factor (G-CSF) | |
| 650 | 4 | |a GBS, Guillain-Barré syndrome | |
| 650 | 4 | |a GM-CSF, granulocyte-macrophage colony-stimulating factor | |
| 650 | 4 | |a HCoV, Human coronavirus | |
| 650 | 4 | |a HCoV-229E, Human coronavirus 229E | |
| 650 | 4 | |a HCoV-OC43, Human coronavirus OC43 | |
| 650 | 4 | |a ICU, intensive care unit | |
| 650 | 4 | |a IL, interleukin | |
| 650 | 4 | |a MCP-1, monocyte chemoattractant protein-1 | |
| 650 | 4 | |a MERS, Middle East respiratory syndrome | |
| 650 | 4 | |a MERS-CoV, Middle East respiratory syndrome coronavirus | |
| 650 | 4 | |a Neurologic manifestations | |
| 650 | 4 | |a PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses | |
| 650 | 4 | |a SARS, severe acute respiratory syndrome | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 | |
| 650 | 4 | |a SARS‐CoV, severe acute respiratory syndrome coronavirus | |
| 650 | 4 | |a βCoV, betacoronavírus | |
| 700 | 1 | |a Feitosa, Pedro Walisson Gomes |e verfasserin |4 aut | |
| 700 | 1 | |a Moreira, Jorge Lucas de Sousa |e verfasserin |4 aut | |
| 700 | 1 | |a Nogueira, Samuel Átila Rodrigues |e verfasserin |4 aut | |
| 700 | 1 | |a Fonseca, Ricardo Brandão |e verfasserin |4 aut | |
| 700 | 1 | |a Nobre, Maria Elizabeth Pereira |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurology, psychiatry, and brain research |d 1997 |g 37(2020) vom: 15. Sept., Seite 27-32 |w (DE-627)NLM092538940 |x 0941-9500 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2020 |g day:15 |g month:09 |g pages:27-32 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.npbr.2020.05.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2020 |b 15 |c 09 |h 27-32 | ||